These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 19950698

  • 1. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 2. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY, Shen YM, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [Abstract] [Full Text] [Related]

  • 3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 4. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 5. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
    Fan Z, Zhang R, Shen YM, Fei HR, Zhu ZL, Cen JN.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep 20; 29(9):611-4. PubMed ID: 19175989
    [Abstract] [Full Text] [Related]

  • 6. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep 20; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 7. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF, Liu Y, Liu P, Jia MF, Cheng J, Zhao L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug 20; 19(4):916-20. PubMed ID: 21867614
    [Abstract] [Full Text] [Related]

  • 8. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2011 Aug 20; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 9. [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
    Shen YM, Chao HY, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.
    Zhonghua Nei Ke Za Zhi; 2009 Feb 20; 48(2):140-3. PubMed ID: 19549471
    [Abstract] [Full Text] [Related]

  • 10. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec 20; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 11. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
    Ruan GR, Chen SS, Li LD, Liu YR, Qin YZ, Li JL, Ma X, Wang FR, Jiang Q, Jiang B, Liu KY, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2007 Sep 11; 87(34):2401-4. PubMed ID: 18036317
    [Abstract] [Full Text] [Related]

  • 12. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi AM, Fabris F, Randi ML.
    Ann Hematol; 2017 Aug 11; 96(8):1297-1302. PubMed ID: 28585070
    [Abstract] [Full Text] [Related]

  • 13. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM, Masala G, Antonioli E, Chiara Susini M, Guglielmelli P, Pieri L, Maggi L, Caini S, Palli D, Bogani C, Ponziani V, Pancrazzi A, Annunziato F, Bosi A.
    Cancer Epidemiol Biomarkers Prev; 2009 Jul 11; 18(7):2068-73. PubMed ID: 19531676
    [Abstract] [Full Text] [Related]

  • 14. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
    Fei HR, Zhang R, Chen SN, Pan JL, Cen JN, Xue YQ.
    Zhonghua Nei Ke Za Zhi; 2007 Apr 11; 46(4):271-3. PubMed ID: 17637260
    [Abstract] [Full Text] [Related]

  • 15. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
    Li ZC, Fu HJ, Wang ZM, Yang S, Xu HZ.
    Genet Mol Res; 2016 Aug 29; 15(3):. PubMed ID: 27706633
    [Abstract] [Full Text] [Related]

  • 16. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb 29; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
    Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC, Chang CS, Lin SF.
    Exp Hematol; 2007 Nov 29; 35(11):1704-7. PubMed ID: 17920754
    [Abstract] [Full Text] [Related]

  • 19. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.
    Leukemia; 2008 Jul 29; 22(7):1299-307. PubMed ID: 18496562
    [Abstract] [Full Text] [Related]

  • 20. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
    Zhang Y, Li L, Nie L, Yu Y, Yang YH, Zhang ZQ, Yang L, Xu SC, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb 29; 29(2):105-9. PubMed ID: 18681311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.